Flumazenil: The Essential Benzo Antagonist for Overdose and Sedation Reversal

Flumazenil stands as a critical medication in emergency medicine and anesthesia, primarily recognized as a Benzo Antagonist. This vital pharmaceutical intervention is frequently deployed in scenarios involving benzodiazepine overdose and to counteract excessive sedation induced by benzodiazepine anesthetics post-surgery. Officially approved by the FDA, flumazenil injection is indicated for the comprehensive or partial reversal of the sedative impacts of benzodiazepines during conscious sedation and general anesthesia, applicable to both adult and pediatric patients. This educational resource is designed to provide a thorough understanding of flumazenil, encompassing its approved uses, mechanism of action, appropriate dosages, potential adverse effects, contraindications, necessary monitoring protocols, and toxicity profiles. By equipping clinicians with this detailed knowledge, the aim is to optimize patient care strategies when employing benzodiazepine reversal agents. The ultimate goal is to enhance the competency of healthcare professionals in utilizing flumazenil therapy effectively, promoting collaborative practices, and refining patient treatment plans tailored to individual needs in cases of benzodiazepine-related emergencies.

Indications for Flumazenil: FDA-Approved and Off-Label Uses of a Benzo Antagonist

Flumazenil is definitively classified as a benzo antagonist, playing a crucial role in reversing the effects of benzodiazepines in various clinical settings.

FDA-Approved Indications

Flumazenil has received FDA approval for several key indications:

Benzodiazepine Overdose Treatment: Flumazenil is a recognized antidote for benzodiazepine overdose in both adult (Category B, Class IIa) and pediatric (Category C, Class IIb) populations. It effectively counteracts the central nervous system depressant effects of benzodiazepines, making it indispensable in emergency situations.
Postoperative Sedation Reversal: Following surgical procedures where benzodiazepine anesthetics are used, flumazenil serves as a reversal agent to expedite patient recovery. This application is approved for both adult (Category B, Class IIa) and pediatric (Category B, Class IIa) patients, aiding in quicker emergence from anesthesia and reduced post-operative monitoring time.
Conscious Sedation and General Anesthesia Reversal: Flumazenil is specifically indicated for reversing the sedative effects of benzodiazepines in conscious sedation and general anesthesia across all age groups. Its use facilitates faster recovery from sedation after minor surgical interventions, leading to shorter post-operative observation periods and enabling earlier patient discharge.
Management of Benzodiazepine-Induced Coma: In cases of coma resulting from benzodiazepine overdose, flumazenil is a valuable tool for reversing the comatose state. It is particularly effective in scenarios of pure benzodiazepine intoxication, demonstrating less efficacy when multiple drugs are involved in the overdose.

Off-Label Uses

Beyond its FDA-approved indications, flumazenil has been utilized off-label in various clinical contexts:

Alcohol Withdrawal Syndrome: Although not a standard treatment, flumazenil has been explored for managing alcohol withdrawal symptoms in specific cases.
Baclofen Reversal: Flumazenil has shown potential in reversing the central nervous system depression caused by baclofen overdose.
Idiopathic Recurring Stupor: In rare cases of unexplained recurrent stupor, flumazenil has been used diagnostically and therapeutically.
Cannabis Toxicity: Emerging evidence suggests a possible role for flumazenil in managing severe cannabis toxicity, particularly in cases of excessive sedation.
Hepatic Encephalopathy: Flumazenil has been investigated for its potential to temporarily improve symptoms of hepatic encephalopathy, although it does not offer long-term survival benefits.
Benzodiazepine Detoxification: In certain detoxification protocols, flumazenil infusion has been used to aid in benzodiazepine withdrawal management, although this remains an area of ongoing research and is not a widely accepted practice due to potential risks.

Mechanism of Action: How This Benzo Antagonist Works

Flumazenil functions as a competitive benzo antagonist. Its primary mechanism involves competitively inhibiting the activity of benzodiazepines and non-benzodiazepine substances that interact with the benzodiazepine receptor site on the GABA/benzodiazepine receptor complex in the central nervous system. Essentially, flumazenil blocks benzodiazepines from binding to their receptors, effectively reversing their effects. Furthermore, flumazenil can displace benzodiazepines that are already bound to these receptors, accelerating the reversal process. Intravenous administration of flumazenil rapidly antagonizes the sedative effects, memory impairment, and psychomotor deficits induced by benzodiazepines.

Pharmacokinetics of Flumazenil

Understanding the pharmacokinetic properties of flumazenil is crucial for effective clinical application:

Absorption and Onset: Following intravenous administration, flumazenil exhibits a rapid onset of action, typically within 1 to 2 minutes. A significant response, around 80%, is usually observed within the first 3 minutes post-administration. The peak effect is generally reached between 6 to 10 minutes after injection.
Duration of Action: The duration of flumazenil’s effects varies from 19 to 50 minutes. This variability is influenced by the administered dose of flumazenil and the plasma concentrations of the benzodiazepine being antagonized. Due to its relatively short duration, repeated administration or continuous infusion may be necessary, especially with longer-acting benzodiazepines.
Distribution: Flumazenil demonstrates extensive distribution throughout the extracellular space in the body. The initial apparent volume of distribution is approximately 0.5 L/kg, increasing to a steady-state volume of 0.9 to 1.1 L/kg. Plasma protein binding is around 50%, with albumin being the primary binding protein, accounting for about two-thirds of this binding.
Metabolism: Flumazenil undergoes almost complete metabolism in the liver. The metabolites are primarily inactive.
Elimination: Elimination of flumazenil is rapid, with radiolabeled studies showing complete elimination within 72 hours. The majority, 90% to 95%, of the drug is excreted in the urine, with a smaller fraction, 5% to 10%, excreted in the feces. Hepatic metabolism is the primary route of clearance. In healthy volunteers, total clearance rates range from 0.8 to 1.0 L/hr/kg. The elimination half-life is approximately 54 minutes, with a variability of about 21% (ranging from 41 to 79 minutes). This relatively short half-life is clinically significant because re-sedation can occur within 1 to 2 hours after administration, necessitating careful monitoring and potential repeat dosing.

Administration and Dosage of Flumazenil

Flumazenil is exclusively formulated for intravenous (IV) infusion.

Available Dosage Forms and Strengths

Flumazenil is available as an injectable solution with a concentration of 0.1 mg/mL. Once drawn into a syringe or mixed with common IV solutions such as D5W (5% dextrose in water), Lactated Ringer’s (LR), or normal saline (NS), the solution remains stable for 24 hours. Administration is typically performed via a free-flowing IV infusion into a large vein or through a series of small, fractionated injections.

Adult Dosage Guidelines

Dosage recommendations for adults vary depending on the clinical scenario:

For Benzodiazepine Overdose Management (FDA Dosage):

Initial Dose: Administer 0.2 mg IV over 30 seconds.
Repeat Dosing: If the desired level of consciousness is not achieved after 30 seconds, administer an additional 0.3 mg IV over 30 seconds.
Subsequent Doses: Repeat doses of 0.5 mg IV over 30 seconds at 1-minute intervals, up to a maximum cumulative dose of 3 mg.
Maximum Total Dose: In patients who show a partial response to 3 mg, further slow titration up to a total dosage of 5 mg may be considered. If no response is observed after 5 mg, benzodiazepine-induced sedation is unlikely to be the primary cause, and further flumazenil administration is generally ineffective.
Re-sedation: In cases of recurrent sedation, repeat doses can be administered at 20-minute intervals, not exceeding 1 mg (0.5 mg/minute) per dose or 3 mg per hour.

For Benzodiazepine Reversal in Conscious Sedation or General Anesthesia (FDA Dosage):

Initial Dose: Administer 0.2 mg IV over 15 seconds.
Repeat Dosing: If the desired level of consciousness is not attained after 45 seconds, repeat 0.2 mg IV at 1-minute intervals. Up to a maximum of 4 additional doses may be given if needed.
Maximum Total Cumulative Dose: The maximum total cumulative dose is 1 mg in this setting.
Re-sedation: For recurrent sedation, repeat doses can be given at 20-minute intervals, not exceeding 0.2 mg/minute per dose or 3 mg per hour in total.

It is important to note that while flumazenil may produce transient improvements in hepatic encephalopathy, the American Association for the Study of Liver Diseases indicates it does not provide long-term survival benefits in this condition.

Dosage Adjustments for Specific Patient Populations

Specific patient populations may require dosage adjustments:

Hepatic Impairment: Patients with hepatic insufficiency require modified dosing. While the initial dose for benzodiazepine reversal remains the same, subsequent doses should be reduced in dosage or frequency due to decreased flumazenil metabolism.
Renal Impairment: According to FDA labeling, no specific dosage adjustments are typically needed for renal impairment unless significant hepatic dysfunction is also present.
Pregnancy Considerations: Flumazenil is classified as Pregnancy Category C. While supportive measures are often sufficient for benzodiazepine toxicity in pregnant individuals, there are case reports suggesting flumazenil can reverse fetal cardiac rhythm abnormalities caused by maternal benzodiazepine overdose. Its use in pregnancy should be carefully considered, weighing the risks and benefits.
Breastfeeding Considerations: Caution is advised when administering flumazenil to breastfeeding women as its presence in human milk is not well-established. Limited data exists on its use during breastfeeding. If flumazenil is necessary for the mother, breastfeeding can continue. Given the drug’s half-life of approximately 54 minutes, abstaining from breastfeeding for 4 to 5 hours post-administration can help minimize infant exposure.
Pediatric Patients: Flumazenil is FDA-approved for benzodiazepine reversal in conscious sedation or general anesthesia in pediatric patients.
- Initial Dose: 0.01 mg/kg administered IV over 15 seconds (up to a maximum dose of 0.2 mg).
- Repeat Dosing: If the desired level of consciousness is not achieved after 45 seconds, repeat 0.01 mg/kg (up to 0.2 mg) at 1-minute intervals as needed, for up to 4 additional doses.
- Maximum Total Cumulative Dose: The maximum total cumulative dose is 1 mg or 0.05 mg/kg, whichever is lower. Clinical trials have shown a mean total dose of 0.65 mg (range: 0.08 to 1 mg) in pediatric use.
Older Patients: Studies in patients over 65, including those over 80, suggest that while benzodiazepine doses for sedation should be reduced in older adults, the standard flumazenil dosage remains effective for reversal in this population.

Adverse Effects of Flumazenil

While flumazenil is generally safe when used appropriately, it is associated with potential adverse effects, ranging from common to serious.

Serious Adverse Events

Serious adverse events associated with flumazenil include:

Seizures: Flumazenil can precipitate seizures, particularly in patients with benzodiazepine dependence or mixed drug overdoses, especially involving tricyclic antidepressants.
Arrhythmias: Cardiac arrhythmias have been reported, although less frequently.
Neurologic Effects: Neurological complications, although less common than seizures, can occur.
Re-sedation: Due to its short half-life, sedation can recur as the effects of flumazenil wear off, especially with long-acting benzodiazepines.

Common Adverse Events

Common adverse events are more frequently observed and typically less severe:

Cardiovascular:

Bradycardia (slow heart rate)
Tachycardia (fast heart rate)
Hypertension (high blood pressure)
Chest pain

Neurologic:

Confusion
Dizziness
Headache
Impaired cognition
Opisthotonus (muscle spasms causing hyperextension and arching of the back)
Shivering
Somnolence (drowsiness)

Gastrointestinal:

Nausea
Vomiting

Immunologic:

Injection site reaction (pain, redness, swelling)

Ophthalmic:

Visual field defects
Diplopia (double vision)
Blurred vision

Otic:

Transient hearing impairment

Dermatologic:

Diaphoresis (excessive sweating)
Injection site pain

Psychiatric:

Anxiety
Agitation
Panic attack
Psychotic disorder

Drug-Drug Interactions

Significant drug-drug interactions to consider with flumazenil include:

Tricyclic Antidepressants (TCAs): Caution is paramount when using flumazenil in mixed drug overdoses, especially those involving TCAs like amitriptyline, nortriptyline, clomipramine, and imipramine. The risk of seizures is significantly increased in these scenarios. In severe TCA toxicity characterized by dysrhythmias, anticholinergic signs, and cardiovascular collapse, flumazenil should be avoided. Supportive care should be prioritized until TCA toxicity symptoms subside.
Vecuronium: A practical concern is the potential for medication errors due to the similar appearance of flumazenil and vecuronium vials, particularly after removing colored caps. Both may be present in procedural areas, increasing the risk of mix-ups.

Contraindications and Precautions for Benzo Antagonist Use

Contraindications

Flumazenil is contraindicated in the following situations:

Hypersensitivity: Known hypersensitivity to flumazenil or benzodiazepines.
Benzodiazepine Use for Life-Threatening Conditions: When benzodiazepines are used to control life-threatening conditions like increased intracranial pressure or status epilepticus, flumazenil is contraindicated as reversing the benzodiazepine effect could be detrimental.

Warnings and Precautions

Several warnings and precautions should be considered when using flumazenil:

Panic Disorder: Flumazenil can provoke panic attacks in patients with a history of panic disorder.
Seizure Risk in Benzodiazepine Dependence: Convulsions may occur in patients with chronic benzodiazepine dependence due to rapid withdrawal.
Head Injury: Flumazenil may precipitate convulsions or alter cerebral blood flow in patients with head injuries.
Epileptic Patients: Increased risk of seizures exists in epileptic patients who have been on benzodiazepine treatment for prolonged periods.
Drug Dependency and Alcoholism: Caution is advised in patients with drug dependency or alcoholism due to the higher likelihood of benzodiazepine tolerance and dependence.
Severe Lung Disease: Do not use flumazenil as the primary treatment in patients with severe lung disease where respiratory depression is secondary to benzodiazepines.
Tricyclic Antidepressant Overdose: Signs of tricyclic antidepressant overdose or mixed overdoses (especially with TCAs) are a strong precaution, and flumazenil is generally not recommended in these cases due to the increased risk of seizures.

US Box Warning

Currently, flumazenil does not carry a US Box Warning, but the aforementioned contraindications and precautions highlight the critical need for careful patient selection and monitoring.

Monitoring Patients Post-Flumazenil Administration

Post-administration monitoring is essential to ensure patient safety and efficacy of flumazenil.

Respiratory Depression and Benzodiazepine Withdrawal: Patients should be monitored for at least 2 hours for signs of respiratory depression, benzodiazepine withdrawal symptoms, and any residual benzodiazepine effects.
Seizure Monitoring: Seizures can occur following flumazenil administration. If seizures are induced, they may require treatment with larger doses of benzodiazepines than initially used for sedation.
Re-sedation: Monitor closely for the possible return of sedation, particularly in patients who are tolerant to benzodiazepines or in cases of long-acting benzodiazepine overdose. Re-sedation can be managed by administering repeat doses of flumazenil until the desired therapeutic effect is achieved.

Toxicity and Management of Flumazenil Overdose

Flumazenil overdose is rare but can occur.

Clinical Features of Toxicity

Clinical features of flumazenil toxicity, though infrequent, may include:

Anxiety
Agitation
Increased muscle tone (hypertonia)
Hyperesthesia (increased sensitivity to stimulation)
Seizures

Management of Toxicity

No Specific Antidote: There is no specific antidote for flumazenil toxicity.
Symptomatic and Supportive Treatment: Management focuses on symptomatic and supportive care, addressing symptoms as they arise.

When to Consult a Specialist

Severe Adverse Effects: Consult a medical toxicologist or local poison control center for any patient exhibiting severe adverse effects after receiving flumazenil, such as seizures, dysrhythmias, and hypotension.

Enhancing Healthcare Team Outcomes with Benzo Antagonist Expertise

In the context of increasing drug overdoses, it is crucial for nurses, pharmacists, and physicians to be proficient in the use of flumazenil as a benzo antagonist. While initially viewed with significant enthusiasm, current expert consensus suggests that the risks of flumazenil may, in many situations, outweigh its benefits. A key concern is the inconsistent and unpredictable nature of flumazenil’s effects. It carries the risk of precipitating seizures and withdrawal in patients chronically using benzodiazepines for medical conditions. Therefore, healthcare providers must be acutely aware of contraindications, particularly in patients with a history of seizures, head injury, or ingestion of tricyclic antidepressants. The ideal scenario for flumazenil use is typically in cases of benzodiazepine overdose in benzodiazepine-naive individuals.

Nurses and pharmacists play a pivotal role in patient education regarding benzodiazepine use, emphasizing the potential for addiction and physical dependence. In isolated benzodiazepine overdoses, mortality is rare, and supportive management often suffices. However, complications such as rhabdomyolysis and aspiration pneumonia can occur. The role of flumazenil in routine benzodiazepine overdose management is diminishing due to the potential for adverse outcomes.

Emergency department clinicians typically manage flumazenil administration in overdose situations. Hospital pharmacists are essential in ensuring accurate dosing. Critical care consultation is necessary for severe poisoning cases with respiratory depression, and medical toxicologist consultation is often required for multiple-drug ingestions. Collaborative efforts among clinicians (MDs, DOs, NPs, and PAs), nurses, and pharmacists are paramount to optimize patient outcomes, maximize the efficacy of flumazenil when appropriate, and minimize associated risks through an interprofessional team approach.

References

1.Baandrup L, Ebdrup BH, Rasmussen JØ, Lindschou J, Gluud C, Glenthøj BY. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane Database Syst Rev. 2018 Mar 15;3(3):CD011481.

2.Zhu S, Noviello CM, Teng J, Walsh RM, Kim JJ, Hibbs RE. Structure of a human synaptic GABAA receptor. Nature. 2018 Jul;559(7712):67-72.

3.Practice Guidelines for Moderate Procedural Sedation and Analgesia 2018: A Report by the American Society of Anesthesiologists Task Force on Moderate Procedural Sedation and Analgesia, the American Association of Oral and Maxillofacial Surgeons, American College of Radiology, American Dental Association, American Society of Dentist Anesthesiologists, and Society of Interventional Radiology. Anesthesiology. 2018 Mar;128(3):437-479.

4.Seelhammer TG, DeGraff EM, Behrens TJ, Robinson JC, Selleck KL, Schroeder DR, Sprung J, Weingarten TN. [The use of flumazenil for benzodiazepine associated respiratory depression in postanesthesia recovery: risks and outcomes]. Braz J Anesthesiol. 2018 Jul-Aug;68(4):329-335.

5.Wu Q, Xu F, Wang J, Jiang M. Comparison of Remimazolam-Flumazenil versus Propofol for Recovery from General Anesthesia: A Systematic Review and Meta-Analysis. J Clin Med. 2023 Nov 26;12(23).

6.Nelson LS. Alcohol withdrawal and flumazenil: not for the faint of heart. J Med Toxicol. 2014 Jun;10(2):123-5.

7.Franchitto N, Pelissier F, Lauque D, Simon N, Lançon C. Self-intoxication with baclofen in alcohol-dependent patients with co-existing psychiatric illness: an emergency department case series. Alcohol Alcohol. 2014 Jan-Feb;49(1):79-83.

8.Asthana V, Agrawal S, Goel D, Sharma JP. Idiopathic recurrent stupor mimicking status epilepticus. Singapore Med J. 2008 Oct;49(10):e276-7.

9.Crippa JA, Derenusson GN, Chagas MH, Atakan Z, Martín-Santos R, Zuardi AW, Hallak JE. Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature. Harm Reduct J. 2012 Jan 25;9:7.

10.Reinert JP, Burnham K. Non-Lactulose Medication Therapies for the Management of Hepatic Encephalopathy: A Literature Review. J Pharm Pract. 2021 Dec;34(6):922-933.

11.Benini A, Gottardo R, Chiamulera C, Bertoldi A, Zamboni L, Lugoboni F. Continuous Infusion of Flumazenil in the Management of Benzodiazepines Detoxification. Front Psychiatry. 2021;12:646038.

12.An H, Godwin J. Flumazenil in benzodiazepine overdose. CMAJ. 2016 Dec 06;188(17-18):E537.

13.Amrein R, Hetzel W, Hartmann D, Lorscheid T. Clinical pharmacology of flumazenil. Eur J Anaesthesiol Suppl. 1988;2:65-80.

14.van Rij CM, Huitema AD, Swart EL, Greuter HN, Lammertsma AA, van Loenen AC, Franssen EJ. Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations. Br J Clin Pharmacol. 2005 Nov;60(5):477-85.

15.Kiyama S. Re-sedation after a large dose of flumazenil. J Anesth. 2023 Feb;37(1):161.

16.Parthvi R, Mehra S. Flumazenil for Mixed Drug Overdose. Am J Ther. 2018 Nov/Dec;25(6):e676-e677.

17.Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014 Aug;60(2):715-35.

18.Janssen U, Walker S, Maier K, von Gaisberg U, Klotz U. Flumazenil disposition and elimination in cirrhosis. Clin Pharmacol Ther. 1989 Sep;46(3):317-23.

19.Zelner I, Matlow J, Hutson JR, Wax P, Koren G, Brent J, Finkelstein Y., Toxicology Investigators Consortium (ToxIC). Acute Poisoning During Pregnancy: Observations from the Toxicology Investigators Consortium. J Med Toxicol. 2015 Sep;11(3):301-8.

20.Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Aug 15, 2023. Flumazenil.

21.Penninga EI, Graudal N, Ladekarl MB, Jürgens G. Adverse Events Associated with Flumazenil Treatment for the Management of Suspected Benzodiazepine Intoxication–A Systematic Review with Meta-Analyses of Randomised Trials. Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):37-44.

22.Wong M. Reversal Agents in Sedation and Anesthesia Practice for Dentistry. Anesth Prog. 2022 Apr 01;69(1):49-58.

23.Veiraiah A, Dyas J, Cooper G, Routledge PA, Thompson JP. Flumazenil use in benzodiazepine overdose in the UK: a retrospective survey of NPIS data. Emerg Med J. 2012 Jul;29(7):565-9.

24.Grissinger M. Paralyzed by Mistakes – Reassess the Safety of Neuromuscular Blockers in Your Facility. P T. 2019 Mar;44(3):91-107.

25.Woolf AD, Erdman AR, Nelson LS, Caravati EM, Cobaugh DJ, Booze LL, Wax PM, Manoguerra AS, Scharman EJ, Olson KR, Chyka PA, Christianson G, Troutman WG. Tricyclic antidepressant poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila). 2007;45(3):203-33.

26.Seger DL. Flumazenil–treatment or toxin. J Toxicol Clin Toxicol. 2004;42(2):209-16.

27.Haverkos GP, DiSalvo RP, Imhoff TE. Fatal seizures after flumazenil administration in a patient with mixed overdose. Ann Pharmacother. 1994 Dec;28(12):1347-9.

28.Sivilotti ML. Flumazenil, naloxone and the ‘coma cocktail’. Br J Clin Pharmacol. 2016 Mar;81(3):428-36.

29.Lavonas EJ, Akpunonu PD, Arens AM, Babu KM, Cao D, Hoffman RS, Hoyte CO, Mazer-Amirshahi ME, Stolbach A, St-Onge M, Thompson TM, Wang GS, Hoover AV, Drennan IR., American Heart Association. 2023 American Heart Association Focused Update on the Management of Patients With Cardiac Arrest or Life-Threatening Toxicity Due to Poisoning: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2023 Oct 17;148(16):e149-e184.

30.Spivey WH. Flumazenil and seizures: analysis of 43 cases. Clin Ther. 1992 Mar-Apr;14(2):292-305.

31.Rousseau-Blass F, Cribb AE, Beaudry F, Pang DS. A Pharmacokinetic-Pharmacodynamic Study of Intravenous Midazolam and Flumazenil in Adult New Zealand White-Californian Rabbits (Oryctolagus cuniculus). J Am Assoc Lab Anim Sci. 2021 May 01;60(3):319-328.

32.Maxa JL, Ogu CC, Adeeko MA, Swaner TG. Continuous-infusion flumazenil in the management of chlordiazepoxide toxicity. Pharmacotherapy. 2003 Nov;23(11):1513-6.

33.Wallace IR, Campbell EC, Trimble M. Use of a flumazenil infusion to treat chlordiazepoxide toxicity. Acute Med. 2017;16(1):30-34.

34.Vukcević NP, Ercegović GV, Segrt Z, Djordjević S, Stosić JJ. Benzodiazepine poisoning in elderly. Vojnosanit Pregl. 2016 Mar;73(3):234-8.

35.Kreshak AA, Cantrell FL, Clark RF, Tomaszewski CA. A poison center’s ten-year experience with flumazenil administration to acutely poisoned adults. J Emerg Med. 2012 Oct;43(4):677-82.

36.Tamburin S, Faccini M, Casari R, Federico A, Morbioli L, Franchini E, Bongiovanni LG, Lugoboni F. Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence. J Psychopharmacol. 2017 Oct;31(10):1369-1373.

37.Tae CH, Kang KJ, Min BH, Ahn JH, Kim S, Lee JH, Rhee PL, Kim JJ. Paradoxical reaction to midazolam in patients undergoing endoscopy under sedation: Incidence, risk factors and the effect of flumazenil. Dig Liver Dis. 2014 Aug;46(8):710-5.

38.Isbister GK, O’Regan L, Sibbritt D, Whyte IM. Alprazolam is relatively more toxic than other benzodiazepines in overdose. Br J Clin Pharmacol. 2004 Jul;58(1):88-95.